From: The Importance of Neuromonitoring in Non Brain Injured Patients
Type | Methodology | Strengths (S) and limitations (L) | Action of medications |
---|---|---|---|
EEG | EEG gives information about cortical | S: Global information of cerebral activity | Ketamine increases the activity of excitatory |
 | activity | L: EEG trace needs experienced operators for | neurons and high frequency oscillations |
 | Global information Scalp electrodes | interpretation | Nitrous oxide increases the amplitude of high frequency activity |
 |  |  | Dexmedetomidine causes slow oscillations with deeper sedation but easily awakened patient |
 |  |  | Propofol increases theta, alpha, spindle beta power, slow waves and delta activity |
pEEG | Translation between analogic signal of | S: Bedside application | Ketamine increases the activity of excitatory |
 | EEG to digital (numeric). Awake | S: Easy interpretation | neurons and high frequency oscillations |
 | status = 100; general anesthesia = 40–60; | S: Availability | Nitrous oxide increases the amplitude of high |
 | suppressed EEG = 0 | L: Muscle artifact | frequency activity |
 | Regional information | L: Translation between analogic signal of | Dexmedetomidine causes slow oscillations |
 | Adhesive pads | EEG to digital | with deeper sedation but easily awakened |
 | DSA is a colored trace obtained from | L: Delay between event and measure | patient |
 | EEG frequencies and transformed into | L: Cerebral activity in limited area (frontal) | Propofol induces slow waves, until suppressed |
 | decibels of bi-hemispheric activity that | L: Several noisy elements can interfere with | pEEG with increases in dosage |
 | can change from red (more frequent) to blue (rare) | the signal L: Effects of medications | Sevoflurane effects on BIS are unclear |
 |  | L: Validation in non-older adults |  |
Type | Methodology | Strengths (S) and limitations (L) | Action of medications |
SSEPs | SSEPs measured by stimulating a peripheral sensory nerve and recording the signal transmitted to the sensory cortex Bedside application | S: Bedside application S: Availability L: Interference with electric devices L: Interpretation by expert | Ketamine increases cortical SSEP amplitude Dexmedetomidine affects amplitude minimally Propofol has minimal effects on SSEPs. Sevoflurane affects SSEPs in a dose-dependent way Barbiturates increase latency and decrease amplitude of SSEPs Benzodiazepines reduce amplitude and increase latency Opioids do not significantly affect SSEPs, but remifentanil prolongs SSEP latency |
MEPs | MEPs measured by transcranial stimulation of the cortex and recording the signal at the spinal cord level, peripheral motor nerves, or the muscles | S: Bedside application S: Availability L: Interference with electric devices L: Interpretation by expert equipment | Ketamine increases amplitude at increased frequency of MEPs Dexmedetomidine causes a decrease in MEP amplitude Propofol has excitatory effects on MEPs Sevoflurane has a depressant effect on MEPs Benzodiazepines attenuate MEPs |
TCD | Investigation of local blood flow and velocities in the circle of Willis 2Â mHz probe placed in acoustic windows (i.e., transtemporal) Measure of nICP and eCPP Cerebral autoregulation Critical closing pressure Diastolic closing margin Midline shift Emboli, obstruction, stenosis | S: Bedside application S: Availability L: Need for experienced operators L: Availability of windows | Ketamine may affect cerebral hemodynamics Propofol decreases the tone of the venous capacitance vessels and decreases cerebral metabolism Remifentanil reduces cerebral blood flow velocity despite constant perfusion pressure Thiopental decreases CBF velocities Benzodiazepines decrease CBF velocity |
ONSD | Measure of nICP and eCPP | S: Bedside application S: Easy interpretation S: Availability | ONSD is larger with propofol in comparison to sevoflurane |
Pupillometry | Pupillometry measures the diameter of | S: Bedside application | Remifentanil determines miosis and reduces |
 | the pupils and the pupillary light reflex | S: Easy interpretation | PLR |
 | NPi is an algorithm using parameters to | S: Availability | Propofol determines miosis and reduces CV |
 | determine pupillary light response, with a | L: Agitated or confused patients can be | Barbiturate titrated to burst suppression |
 | scale 0–5, < 3 is abnormal | difficult to evaluate | reduces CV |
 | Maximum and minimum pupil diameter | L: Patients with scleral edema, periorbital | Droperidol causes miosis and reduces PDR |
 | (mm) refers to diameter at rest and peak | edema, intraocular lens replacement prior | Metoclopramide causes miosis and reduces |
 | constriction Latency is the time (seconds) delay between light stimulus and pupillary constriction | ocular surgical procedures can limit assessment with pupillometry L: Ambient light can influence the measure L: Expensive | PDR |
 | CV is the distance (mm) of constriction divided by duration (seconds) of constriction |  |  |
 | Dilation velocity is the distance (mm) of re-dilation divided by duration (seconds) of re-dilation |  |  |
ype | Methodology | Strengths (S) and limitations (L) | Action of medications |
NIRS | NIRS measures cerebral oxygen | S: Bedside application | Propofol and dexmedetomidine equally |
 | saturation by using a near-infrared light | S: Easy interpretation | preserve cerebral oxygenation and do not |
 | passing through adhesive pads and | S: Availability | affect neurological outcome |
 | tissues. The light is therefore adsorbed by | L: Regional evaluation of cerebral oximetry | Cerebral oxygenation may be better preserved |
 | oxyhemoglobin and deoxyhemoglobin, thus obtaining a value reflecting the local | that may not reflect global changes in hemodynamics | with sevoflurane than propofol Midazolam and morphine may alter cerebral |
 | amount of oxygen within the frontal region A decrease of 20% from baseline can be associated to the reduction of CBF, hypoperfusion and neurologic symptoms Regional measure | L: Bias with skin color and gender L: Variations due to systemic extracranial perfusion L: Elimination of oxygen degradation products in patients with liver diseases that can alter the absorption of light | oxygenation and hemodynamics |
 | Adhesive pads |  |  |
 | Various devices are available with different algorithms and components, including Masimo (Masimo Corp., Irvine, CA), INVOS (Medtronic, Minneapolis, USA) |  |  |